Anika Therapeutics, Inc. (ANIK)

Sentiment-Signal

22,8
Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)

Score-Verlauf (90 Tage)

Stammdaten

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.

Unternehmen & Branche

NameAnika Therapeutics, Inc.
TickerANIK
CIK0000898437
BoerseUS
SektorHealthcare
IndustrieMedical - Devices
SIC3841 · Surgical & Medical Instruments & Apparatus

Wertpapier & Kennzahlen

CUSIP
ISIN
TypCommon Stock
Marktkapitalisierung223,5 Mio. USD
Beta0,28
Dividendenrendite0,00 %

Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »

Finanzkennzahlen (SEC XBRL)

PeriodeFilingUmsatzNettoergebnisEPSAktivaEigenkapital
2025-12-3110-K112,819,000-10,880,000-0.76190,270,000143,465,000
2025-09-3010-Q27,817,000-2,329,000-0.16189,437,000146,805,000
2025-06-3010-Q28,219,000-3,970,000-0.28187,682,000147,672,000
2025-03-3110-Q26,168,000-4,873,000-0.34190,605,000148,397,000
2024-12-3110-K119,907,000-56,385,000-3.83202,740,000153,989,000
2024-09-3010-Q29,559,000-29,918,000-2.03231,405,000179,864,000
2024-06-3010-Q30,724,000-88,0000.00262,655,000210,338,000
2024-03-3110-Q29,022,000-4,514,000-0.31263,744,000208,536,000
2023-12-3110-K120,792,000-82,667,000-5.64270,632,000212,265,000
2023-09-3010-Q41,465,000-6,576,000-0.45328,158,000270,486,000
2023-06-3010-Q44,302,000-2,741,000-0.19328,882,000274,015,000
2023-03-3110-Q37,924,000-10,350,000-0.71339,074,000277,588,000
2022-12-3110-K113,827,000-14,859,000-1.02349,128,000285,563,000
2022-09-3010-Q40,264,000-4,175,000-0.29347,746,000284,937,000
2022-06-3010-Q39,657,000-2,843,000-0.20354,123,000286,153,000
2022-03-3110-Q36,693,000-2,933,000-0.20342,239,000285,787,000
2021-12-3110-K147,794,0004,134,0000.28347,535,000287,085,000
2021-09-3010-Q39,536,000558,0000.04352,930,000290,060,000
2021-06-3010-Q38,145,0006,531,0000.45363,131,000286,804,000
2021-03-3110-Q34,292,0002,838,0000.20362,253,000276,656,000

Fondsaktivität (Vorquartalsvergleich)

Keine Fondsdaten für dieses Unternehmen vorhanden.

Insider-Transaktionen (12 Monate)

Keine Insider-Käufe/Verkäufe in den letzten 12 Monaten.

Top-Fondshalter

Keine Fondsdaten zu dieser Aktie vorhanden.

Hinweis

Erweitert ×